PL366035A1 - Sposób i kompozycja do leczenia raka przez podawanie środków chemioterapeutycznych wywołujących apoptozę - Google Patents

Sposób i kompozycja do leczenia raka przez podawanie środków chemioterapeutycznych wywołujących apoptozę

Info

Publication number
PL366035A1
PL366035A1 PL01366035A PL36603501A PL366035A1 PL 366035 A1 PL366035 A1 PL 366035A1 PL 01366035 A PL01366035 A PL 01366035A PL 36603501 A PL36603501 A PL 36603501A PL 366035 A1 PL366035 A1 PL 366035A1
Authority
PL
Poland
Prior art keywords
apoptosis
administration
composition
treating cancer
chemotherapeutic agents
Prior art date
Application number
PL01366035A
Other languages
English (en)
Inventor
Moshe Flashner-Barak
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of PL366035A1 publication Critical patent/PL366035A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL01366035A 2000-04-10 2001-04-10 Sposób i kompozycja do leczenia raka przez podawanie środków chemioterapeutycznych wywołujących apoptozę PL366035A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19592000P 2000-04-10 2000-04-10

Publications (1)

Publication Number Publication Date
PL366035A1 true PL366035A1 (pl) 2005-01-24

Family

ID=22723363

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366035A PL366035A1 (pl) 2000-04-10 2001-04-10 Sposób i kompozycja do leczenia raka przez podawanie środków chemioterapeutycznych wywołujących apoptozę

Country Status (19)

Country Link
US (1) US20020041888A1 (pl)
EP (1) EP1274404A1 (pl)
JP (1) JP2004507451A (pl)
KR (1) KR20030008368A (pl)
CN (1) CN1438882A (pl)
AU (1) AU2001253334A1 (pl)
BR (1) BR0110150A (pl)
CA (1) CA2406484A1 (pl)
CZ (1) CZ20023333A3 (pl)
EA (1) EA200201068A1 (pl)
HU (1) HUP0302296A2 (pl)
IL (1) IL152180A0 (pl)
MX (1) MXPA02009984A (pl)
NO (1) NO20024867L (pl)
PL (1) PL366035A1 (pl)
SK (1) SK14452002A3 (pl)
WO (1) WO2001076567A1 (pl)
YU (1) YU77002A (pl)
ZA (1) ZA200208167B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
CA2482941A1 (en) * 2002-04-26 2003-11-06 Teva Pharmaceutical Industries Ltd. Microparticle pharmaceutical compositions for intratumoral delivery
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇-海藻酸钠微球血管栓塞剂及其制备
AU2005299748B2 (en) * 2004-10-21 2009-04-09 Tgel Bio Co., Ltd In situ controlled release drug delivery system
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2601067A1 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
CA2646156C (en) 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
EP3925625A1 (en) * 2011-01-09 2021-12-22 ANP Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use
WO2021138646A1 (en) 2020-01-03 2021-07-08 Privo Technologies, Inc. Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins

Also Published As

Publication number Publication date
AU2001253334A1 (en) 2001-10-23
ZA200208167B (en) 2004-02-10
CN1438882A (zh) 2003-08-27
KR20030008368A (ko) 2003-01-25
MXPA02009984A (es) 2004-09-10
CA2406484A1 (en) 2001-10-18
US20020041888A1 (en) 2002-04-11
CZ20023333A3 (cs) 2003-06-18
WO2001076567A1 (en) 2001-10-18
NO20024867D0 (no) 2002-10-09
IL152180A0 (en) 2003-05-29
NO20024867L (no) 2002-12-06
JP2004507451A (ja) 2004-03-11
SK14452002A3 (sk) 2003-07-01
EA200201068A1 (ru) 2003-12-25
HUP0302296A2 (hu) 2003-10-28
BR0110150A (pt) 2004-04-27
YU77002A (sh) 2005-09-19
EP1274404A1 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1229934A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER BY MEANS OF IMMUNO-CONJUGATES AND CHEMOTHERAPEUTIC AGENTS
AU4768301A (en) Synergistic methods and compositions for treating cancer
EP1355563A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
HUP0203304A3 (en) Method and composition for chemoprevention of prostate cancer
IL152180A0 (en) Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
PL352931A1 (pl) Kompozycje i zastosowanie ET 743 w leczeniu raka
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
AU5160201A (en) Compositions comprising natural agents for treatment of cancer
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU2001278558A1 (en) Use of co for treating inflammation of upper airways or bronchi
EP1463495A4 (en) AGENTS AND METHODS FOR TREATING CANCER
IL145397A0 (en) Compositions and methods for treatment of cancer
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
PL368035A1 (pl) Kompozycje i sposoby leczenia raka
AU2001253836A1 (en) Method of treating cancer
HUP0300860A3 (en) Pharmaceutical compositions suitable for treatment of urinary dysfunction
HUP0302430A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontience
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
IL154354A0 (en) Composition for prophylaxis and treatment of cancer
AUPR644301A0 (en) Method and composition for treatment of cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer